Strategic Brand Planning: Winning by Resource Optimization

Our client was a global biopharmaceutical company with a market-leading brand more than 20 years’ old. It came under intense pricing pressure due to generic entries from companies known to play primarily on price.

Stakeholder Engagement Strategies: Providing a Deeper Understanding of Potential Customers

Our client, a global pharmaceutical company, was in the process of strengthening the vision for its future product portfolio. The marketing team needed to identify potential high-prescribing customers to develop a marketing campaign that would support its strategy for optimally co-positioning future therapies. There were several unknowns about the potential license for our client’s product, so Prescient was engaged to develop strong, focused positioning concepts that would resonate with the emotional needs of target customers.

Phase III Decision Support: Evidence-Based and Objective Risk Assessment

Our client, a global pharmaceutical company, sought to decide whether to progress two internal assets into Phase III development based on the Phase II data. The client engaged Prescient to: 1) perform an in-depth assessment of the Phase II data and comparative analyses with in-line and pipeline competitor products; 2) evaluate the potential changes in the regulatory requirements; 3) analyze the impact of the potential entry of biosimilars and their ability to disrupt the marketplace; and 4) help develop an overarching Phase III design consideration, including endpoints and patient population.

Peri-Launch Support: Defining the Market and Changing Current Practice

Our client, a global pharmaceutical company, planned to launch a new product about six months ahead of a direct competitor in an indication with no effective treatment options. As physicians had many options for acute treatment for this chronic disease, the client engaged Prescient to define the market and help change the current practice.

Market Opportunity Mapping: Identifying Opportunities for a First-in-Class Product in a Crowded Space

Our client, a global pharmaceutical company, needed to identify opportunities in the EU5 countries for a first-in-class injectable product entering a crowded generic market. The client’s product was expected to obtain marketing authorization on the back of positive Phase III trials using surrogate endpoints and not hard clinical endpoints.